Vacaras Vitalie, Paraschiv Andreea-Cristina, Iluț Silvina, Vacaras Cristiana, Nistor Cristina, Marin Gheorghe-Eduard, Schiopu Andra Maria, Nistor Dorian-Traian, Vesa Ștefan Cristian, Mureșanu Dafin Fior
Neurology Department, Cluj Emergency County Hospital, 400012 Cluj-Napoca, Romania.
Department of Neurosciences, Faculty of Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Brain Sci. 2024 Feb 29;14(3):243. doi: 10.3390/brainsci14030243.
Multiple sclerosis (MS) is a demyelinating central nervous system disease that leads to neurological disability. Brain-derived neurotrophic factors (BDNFs) are neurotrophins involved in neurodegenerative disorders. This study analysed the relationship between serum BDNF, neurological disability and different MS treatments. We included 63 people with MS (PwMS), with relapsing-remitting MS or clinically isolated syndrome, and 16 healthy controls (HCs). We analysed the serum levels of BDNF and MS specific disability tests (Expanded Disability Status Scale, timed 25-foot walk test, nine-hole peg test), at baseline (V0) and after one year of interferon beta1a or teriflunomide treatment (V1). Baseline BDNF values were not different between the PwMS and HCs ( = 0.85). The BDNF levels were higher in PwMS vs. HCs after treatment ( = 0.003). BDNF was not related to last-year relapses or by the disease duration (all > 0.05). The overall values for the PwMS decreased after one year ( < 0.001). Both treatments implied a similar reduction. BDNF was not related to neurological disability ( > 0.05). BDNF values were not influenced by the lesion burden, active lesions, or new lesions on MRI ( > 0.05). In our cohort, the PwMS had higher BDNF levels compared to the HCs after one year of treatment. BDNF was not related to clinical or paraclinical disease severity signs.
多发性硬化症（MS）是一种导致神经功能障碍的中枢神经系统脱髓鞘疾病。脑源性神经营养因子（BDNF）是参与神经退行性疾病的神经营养因子。本研究分析了血清BDNF、神经功能障碍与不同MS治疗方法之间的关系。我们纳入了63例复发缓解型MS或临床孤立综合征患者（PwMS）以及16名健康对照者（HCs）。我们在基线期（V0）以及接受干扰素β1a或特立氟胺治疗一年后（V1），分析了BDNF的血清水平以及MS特异性残疾测试（扩展残疾状态量表、25英尺定时步行测试、九孔插钉测试）。PwMS和HCs之间的基线BDNF值无差异（ = 0.85）。治疗后PwMS的BDNF水平高于HCs（ = 0.003）。BDNF与去年的复发或疾病持续时间无关（所有 ＞ 0.05）。PwMS的总体值在一年后下降（ ＜ 0.001）。两种治疗方法导致的下降幅度相似。BDNF与神经功能障碍无关（ ＞ 0.05）。BDNF值不受MRI上的病灶负荷、活动性病灶或新病灶的影响（ ＞ 0.05）。在我们的队列中，治疗一年后PwMS的BDNF水平高于HCs。BDNF与临床或临床旁疾病严重程度体征无关。
